Table 1.
Comparison of Clinical Characteristics Between Wild-Type and Mutant Cbl Family Genes
| Variable* | Cbl Family Mutant (n = 17) | Cbl Family Wild Type (n = 307) | P |
|---|---|---|---|
| Age, years | |||
| ≥ 60 | 10 | 224 | .21 |
| < 60 | 6 | 62 | |
| Sex | |||
| Male | 8 | 183 | .2 |
| Female | 9 | 106 | |
| WBC count, ×109/L | |||
| ≥ 10 | 9 | 93 | .11 |
| < 10 | 8 | 197 | |
| Monocyte count, ×109/L | |||
| ≥ 1 | 13 | 53 | < .0001 |
| < 1 | 4 | 237 | |
| Metaphase cytogetetics | |||
| Abnormal | 10 | 133 | .62 |
| Normal | 7 | 139 | |
| Disease risk† | |||
| Advanced grade | 12 | 141 | .7 |
| Low grade | 4 | 142 | |
| Therapy and response | |||
| Chemotherapy‡ | 14 | 130 | .001 |
| Stem cell transplantation | 4 | 21 | .035 |
| Complete remission | 3 | 22 | .73 |
*
Some clinical data are not available.
†
In advanced group, secondary acute myelogenous leukemia, refractory anemia with excess blasts, and chronic myelomonocytic leukemia 2. The others are in low grade group
‡
Chemotherapy includes mitoxantrone, idarubicin, daunorubicin, cytarabine, etoposide, hydroxyurea, fludarabine gemtuzumab, 5-azacitidine, decitabine, lenalidomide, arsenic trioxide, and valproic acid.